Department of Pharmacy and Pharmacology

barry_potter

Professor of Medicinal and Biological Chemistry

5 West - 3.3

Email: B.V.L.Potter@bath.ac.uk

Tel: +44 (0) 1225 386639

wellcome-trust

Professor Potter's research homepage

 

Prof Barry Potter FMedSci

Profile

Biosketch

Professor Potter studied chemistry at Oxford, completing his D.Phil on the stereochemistry of enzyme-catalysed phosphoryl transfer, developing the [16O,17O,18O] chiral phosphate approach. After postdocs at Oxford and the Max-Planck-Institute for Experimentelle Medizin in Germany he became Lecturer in Biological Chemistry at Leicester, winning a Lister Institute Fellowship, moving to the Established Chair of Medicinal Chemistry at Bath as Head of Section. He is Visiting Professor at Oxford University and, from 2013, a Wellcome Trust Senior Investigator.

Research (see my research homepage) is at Chemistry-Biology and Chemistry-Medicine interfaces, in Signal Transduction, Anticancer Drug Discovery and Translational & Molecular Medicine. Particular interests are synthetic chemical biology tools in cell-signalling by calcium-mobilising second messengers. In Medicinal Chemistry, he has pioneered a new pharmacophore, bringing compounds from novel therapeutic concept to 18 Phase I and II clinical trials in oncology and women’s health. Bath drugs are in human trials in metastatic breast cancer, endometrial cancer, prostate cancer and endometriosis. He co-founded Sterix, a spin-out company acquired by major pharma.

He was a member of the RAE2001 and RAE2008 Panels, 2009 REF Expert Group Panel, Wellcome Trust Molecules, Genes & Cells Funding Panel (2006-2011), BBSRC Intracellular Signalling Programme Committee and the EPSRC Synthetic and Biological Chemistry College and is currently a member of the Wellcome Trust Peer Review College. He is on editorial boards including the Journal of Medicinal Chemistry, Molecular Cancer Therapeutics, ChemMedChem and is Associate Editor of the Journal of Steroid Biochemistry & Molecular Biology and an Editor of the Biochemical Journal's BJChemBio.

Professor Potter is a Fellow of the Royal Society of Chemistry (RSC) and the Society of Biology and Fellow of the Academy of Medical Sciences (2008) and Member of Academia Europaea (2009). He has won major prizes:

  • 2007 RSC Medal for Chemical Biology
  • 2007/8 RSC George and Christine Sosnovsky Medal
  • 2009 RSC Malcolm Campbell Medal
  • 2009 GlaxoSmithKline International Achievement Award
  • 2010 RSC Interdisciplinary Medal 
  • 2012 European Life Sciences Awards "Investigator of the Year"
  • 2015/16 RSC-BMCS Medicinal Chemistry Lectureship

Publications

Fliegert, R., Bauche, A., Wolf Pérez, A.-M., Watt, J. M., Rozewitz, M. D., Winzer, R., Janus, M., Gu, F., Rosche, A., Harneit, A., Flato, M., Moreau, C., Kirchberger, T., Wolters, V., Potter, B. V. L. and Guse, A. H., 2017. 2ʹ-Deoxyadenosine 5ʹ-diphosphoribose is an endogenous TRPM2 superagonist. Nature Chemical Biology, 13, pp. 1036-1044.

Whitfield, H., Riley, A. M., Diogenous, S., Godage, H. Y., Potter, B. and Brearley, C. A., 2017. Simple synthesis of 32P-labelled inositol hexakisphosphates for study of phosphate transformations. Plant and Soil

Fliegert, R., Watt, J. M., Schöbel, A., Rozewitz, M. D., Moreau, C., Kirchberger, T., Thomas, M. P., Sick, W., Araujo, A. C., Harneit, A., Potter, B. V. L. and Guse, A. H., 2017. Ligand induced activation of human TRPM2 requires the terminal ribose of ADPR and involves Arg 1433 and Tyr 1349. Biochemical journal, 474 (13), BCJ20170091.

Thomas, M. P., Erneux, C. and Potter, B. V. L., 2017. SHIP2:structure, function and inhibition. ChemBiochem, 18 (3), pp. 233-247.

Raimondi, C., Calleja, V., Ferro, R., Fantin, A., Riley, A., Potter, B., Brennan, C. H., Maffucci, T., Larijani, B. and Falasca, M., 2016. A Small Molecule Inhibitor of PDK1/PLCγ1 Interaction Blocks Breast and Melanoma Cancer Cell Invasion. Scientific Reports, 6, 26142.

Watson, P. J., Millard, C. J., Riley, A. M., Robertson, N. S., Wright, L. C., Godage, H. Y., Cowley, S. M., Jamieson, A. G., Potter, B. V. L. and Schwabe, J. W. R., 2016. Insights into the activation mechanism of class I HDAC complexes by inositol phosphates. Nature Communications, 7, 11262.

Mills, S. J., Silvander, C., Cozier, G., Trésaugues, L., Nordlund, P. and Potter, B. V. L., 2016. Crystal structures of type-II inositol polyphosphate 5-phosphatase INPP5B with synthetic inositol polyphosphate surrogates reveal new mechanistic insights for the inositol 5-phosphatase family. Biochemistry, 55 (9), pp. 1384-1397.

Thomas, M. P., Mills, S. J. and Potter, B. V. L., 2016. The "other" inositols and their phosphates:synthesis, biology, and medicine (with recent advances in myo-inositol chemistry). Angewandte Chemie-International Edition, 55 (5), pp. 1614-1650.

Shen, Y. C., Upadhyayula, R., Cevallos, S., Messick, R. J., Hsia, T., Leese, M. P., Jewett, D. M., Ferrer-Torres, D., Roth, T. M., Dohle, W., Potter, B. V. L. and Barald, K. F., 2015. Targeted NF1 cancer therapeutics with multiple modes of action:small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol. British Journal of Cancer, 113 (8), pp. 1158-1167.

Stengel, C., Newman, S. P., Leese, M. P., Thomas, M. P., Potter, B. V. L., Reed, M. J., Purohit, A. and Foster, P. A., 2015. The in vitro and in vivo activity of the microtubule disruptor STX140 is mediated by Hif-1 alpha and CAIX expression. Anticancer Research, 35 (10), pp. 5249-5262.

Thomas, M. P. and Potter, B. V. L., 2015. Estrogen O-sulfamates and their analogues:clinical steroid sulfatase inhibitors with broad potential. Journal of Steroid Biochemistry and Molecular Biology, 153, 4391.

Riley, A. M., Wang, H., Shears, S. B. and Potter, B. V. L., 2015. Synthetic tools for studying the chemical biology of InsP8. Chemical Communications, 51 (63), pp. 12605-12608.

Stengel, C., Newman, S. P., Day, J. M., Chander, S. K., Jourdan, F. L., Leese, M. P., Ferrandis, E., Regis-lydi, S., Potter, B. V. L., Reed, M. J., Purohit, A. and Foster, P. A., 2015. In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer. British Journal of Cancer, 111 (2), pp. 300-308.

Swarbrick, J. M., Riley, A. M., Mills, S. J. and Potter, B. V. L., 2015. Designer small molecules to target calcium signalling. Biochemical Society Transactions, 43 (3), pp. 417-425.

Tsuzuki, T., Takano, S., Sakaguchi, N., Kudoh, T., Murayama, T., Sakurai, T., Higashida, H., Weber, K., Guse, A. H., Kameda, T., Hirokawa, T., Kumaki, Y., Arisawa, M., Potter, B. and Shuto, S., 2015. Design, Synthesis, and Chemical and Biological Properties of Cyclic ADP-4-Thioribose as a Stable Equivalent of Cyclic ADP-Ribose. Messenger, 3 (1-2), pp. 35-51.

Nebel, M., Zhang, B., Odoardi, F., Flugel, A., Potter, B. and Guse, A. H., 2015. Calcium Signalling Triggered by NAADP in T Cells Determines Cell Shape and Motility During Immune Synapse Formation. Messenger, 4 (1), pp. 104-111.

Swarbrick, J., Riley, A., Mills, S. and Potter, B., 2015. Designer small molecules to target calcium signalling.

Swarbrick, J. M., Graeff, R., Zhang, H., Thomas, M. P., Hao, Q. and Potter, B. V. L., 2014. Cyclic adenosine 5′-diphosphate ribose analogs without a southern ribose inhibit ADP-ribosyl cyclase-hydrolase CD38. Journal of Medicinal Chemistry, 57 (20), pp. 8517-8529.

Dohle, W., Leese, M.P., Jourdan, F.L., Chapman, C.J., Hamel, E., Ferrandis, E. and Potter, B.V.L., 2014. Optimisation of tetrahydroisoquinoline-based chimeric microtubule disruptors. ChemMedChem, 9 (8), pp. 1783-1793.

Wang, H., Godage, H. Y., Riley, A. M., Weaver, J. D., Shears, S. B. and Potter, B. V. L., 2014. Synthetic inositol phosphate analogs reveal that PPIP5K2 has a surface-mounted substrate capture site that is a target for drug discovery. Chemistry & Biology, 21 (5), pp. 689-699.

Leese, M. P., Jourdan, F. L., Major, M. R., Dohle, W., Thomas, M. P., Hamel, E., Ferrandis, E., Mahon, M. F., Newman, S. P., Purohit, A. and Potter, B. V. L., 2014. Synthesis, anti-tubulin and antiproliferative SAR of steroidomimetic dihydroisoquinolinones. ChemMedChem, 9 (4), pp. 798-812.

Swarbrick, J. M., Graeff, R., Garnham, C., Thomas, M. P., Galione, A. and Potter, B. V. L., 2014. 'Click cyclic ADP-ribose':A neutral second messenger mimic. Chemical Communications, 50 (19), pp. 2458-2461.

Pulloor, N.K., Nair, S., Kostic, A.D., Bist, P., Weaver, J.D., Riley, A.M., Tyagi, R., Uchil, P.D., York, J.D., Snyder, S.H., García-Sastre, A., Potter, B.V.L., Lin, R., Shears, S.B., Xavier, R.J. and Krishnan, M.N., 2014. Human Genome-Wide RNAi Screen Identifies an Essential Role for Inositol Pyrophosphates in Type-I Interferon Response. PLoS Pathogens, 10 (2).

Dohle, W., Leese, M. P., Jourdan, F. L., Major, M. R., Bai, R., Hamel, E., Ferrandis, E., Kasprzyk, P. G., Fiore, A., Newman, S. P., Purohit, A. and Potter, B. V. L., 2014. Synthesis, Antitubulin, and Antiproliferative SAR of C3/C1-Substituted Tetrahydroisoquinolines. ChemMedChem, 9 (2), pp. 350-370.

Riley, A. M., Windhorst, S., Lin, H.-Y. and Potter, B. V. L., 2014. Cellular internalisation of an inositol phosphate visualised by using fluorescent InsP5. ChemBiochem, 15 (1), pp. 57-67.

Leese, M. P., Jourdan, F. L., Major, M.R., Dohle, W., Hamel, E., Ferrandis, E., Fiore, A., Kasprzyk, P. G. and Potter, B. V. L., 2014. Tetrahydroisoquinolinone-based steroidomimetic and chimeric microtubule disruptors. ChemMedChem, 9 (1), pp. 85-108.

Thomas, M. P. and Potter, B. V. L., 2014. The enzymes of human diphosphoinositol polyphosphate metabolism. FEBS Journal, 281 (1), pp. 14-33.

Wang, H., Godage, H., Riley, A., Weaver, J. D., Potter, B. and Shears, S. B., 2014. Synthetic inositol phosphate analogues in complex with PPIP5K2 uncover a substrate capture site as a target for drug discovery. Chemistry & Biology

Moreau, C., Kirchberger, T., Swarbrick, J. M., Bartlett, S. J., Fliegert, R., Yorgan, T., Bauche, A., Harneit, A., Guse, A. H. and Potter, B. V. L., 2013. Structure–ativity relationship of adenosine 5′-diphosphoribose at the transient receptor potential melastatin 2 (TRPM2) channel:rational design of antagonists. Journal of Medicinal Chemistry, 56 (24), pp. 10079-10102.

Tsuzuki, T., Sakaguchi, N., Kudoh, T., Takano, S., Uehara, M., Murayama, T., Sakurai, T., Hashii, M., Higashida, H., Weber, K., Guse, A. H., Kameda, T., Hirokawa, T., Kumaki, Y., Potter, B. V. L., Fukuda, H., Arisawa, M. and Shuto, S., 2013. Design and synthesis of cyclic ADP-4-thioribose as a stable equivalent of cyclic ADP-ribose, a calcium ion-mobilizing second messenger. Angewandte Chemie-International Edition, 52 (26), pp. 6633-6637.

Moreau, C., Liu, Q., Graeff, R., Wagner, G.K., Thomas, M.P., Swarbrick, J.M., Shuto, S., Lee, H.C., Hao, Q. and Potter, B.V.L., 2013. CD38 Structure-Based Inhibitor Design Using the N1-Cyclic Inosine 5′-Diphosphate Ribose Template. PLoS ONE, 8 (6), e66247.

Nebel, M., Schwoerer, A. P., Warszta, D., Siebrands, C. C., Limbrock, A.-C., Swarbrick, J. M., Fliegert, R., Weber, K., Bruhn, S., Hohenegger, M., Geisler, A., Herich, L., Schlegel, S., Carrier, L., Eschenhagen, T., Potter, B. V. L., Ehmke, H. and Guse, A. H., 2013. Nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium signaling and arrhythmias in the heart evoked by β-adrenergic stimulation. Journal of Biological Chemistry, 288 (22), pp. 16017-16030.

Veiga, N., Torres, J., Macho, I., Gómez, K., Godage, H.Y., Riley, A.M., Potter, B.V.L., González, G. and Kremer, C., 2013. Inframolecular acid-base and coordination properties towards Na+ and Mg2+ of myo-inositol 1,3,4,5,6-pentakisphosphate:A structural approach to biologically relevant species. Dalton Transactions, 42 (17), pp. 6021-6032.

Woo, L.W.L., Wood, P.M., Bubert, C., Thomas, M.P., Purohit, A. and Potter, B.V.L., 2013. Synthesis and structure-activity relationship studies of derivatives of the dual aromatase-sulfatase inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate. ChemMedChem, 8 (5), pp. 779-799.

Khan, S. A., Rossi, A. M., Riley, A. M., Potter, B. V.L. and Taylor, C. W., 2013. Subtype-selective regulation of IP3 receptors by thimerosal via cysteine residues within the IP3-binding core and suppressor domain. Biochemical Journal, 451 (2), pp. 177-184.

Godage, H. Y., Riley, A. M., Woodman, T. J., Thomas, M. P., Mahon, M. F. and Potter, B. V. L., 2013. Regioselective opening of myo-inositol orthoesters:Mechanism and synthetic utility. Journal of Organic Chemistry, 78 (6), pp. 2275-2288.

Saleem, H., Tovey, S.C., Riley, A.M., Potter, B.V.L. and Taylor, C.W., 2013. Stimulation of inositol 1,4,5-trisphosphate (IP3) receptor subtypes by Adenophostin A and its analogues. PLoS ONE, 8 (2), e58027.

Day, J.M., Foster, P.A., Tutill, H.J., Schmidlin, F., Sharland, C.M., Hargrave, J.D., Vicker, N., Potter, B.V.L., Reed, M.J. and Purohit, A., 2013. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. Endocrine-Related Cancer, 20 (1), pp. 53-64.

Saleem, H., Tovey, S.C., Rahman, T., Riley, A.M., Potter, B.V.L. and Taylor, C.W., 2013. Stimulation of Inositol 1,4,5-Trisphosphate (IP3) Receptor Subtypes by Analogues of IP3. PLoS ONE, 8 (1), 54877.

Thomas, M. P. and Potter, B. V. L., 2013. The structural biology of oestrogen metabolism. Journal of Steroid Biochemistry and Molecular Biology, 137, pp. 27-49.

Grint, T., Riley, A. M., Mills, S. J., Potter, B. V. L. and Safrany, S. T., 2012. Fibrinogen—a possible extracellular target for inositol phosphates. Messenger, 1 (2), pp. 160-166.

Su, X., Halem, H. A., Thomas, M. P., Moutrille, C., Culler, M. D., Vicker, N. and Potter, B. V. L., 2012. Adamantyl carboxamides and acetamides as potent human 11β- hydroxysteroid dehydrogenase type 1 inhibitors. Bioorganic and Medicinal Chemistry, 20 (21), pp. 6394-6402.

Riley, A. M., Wang, H., Weaver, J. D., Shears, S. B. and Potter, B. V. L., 2012. First synthetic analogues of diphosphoinositol polyphosphates: interaction with PP-InsP5 kinase. Chemical Communications, 48 (92), pp. 11292-11294.

Pradaux-Caggiano, F., Su, X., Vicker, N., Thomas, M. P., Smithen, D., Halem, H. A., Culler, M. D. and Potter, B. V. L., 2012. Synthesis and evaluation of thiadiazole derivatives as inhibitors of 11β-hydroxysteroid dehydrogenase type 1. MedChemComm, 3 (9), pp. 1117-1124.

Mills, S. J., Persson, C., Cozier, G., Thomas, M. P., Trésaugues, L., Erneux, C., Riley, A. M., Nordlund, P. and Potter, B. V. L., 2012. A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery. ACS Chemical Biology, 7 (5), pp. 822-828.

Woo, L. W. L., Leblond, B., Purohit, A. and Potter, B. V. L., 2012. Synthesis and evaluation of analogues of estrone-3-O-sulfamate as potent steroid sulfatase inhibitors. Bioorganic and Medicinal Chemistry, 20 (8), pp. 2506-2519.

Moreau, C., Kirchberger, T., Zhang, B., Thomas, M. P., Weber, K., Guse, A. H. and Potter, B. V. L., 2012. Aberrant cyclization affords a C-6 modified cyclic adenosine 5′-diphosphoribose analogue with biological activity in Jurkat T cells. Journal of Medicinal Chemistry, 55 (4), pp. 1478-1489.

Nebel, M., Schworer, A., Siebrands, C. C., Limbrock, A.-C., Swarbrick, J. M., Hohenegger, M., Geisler, A., Herich, L., Schlegel, S., Carrier, L., Eschenhagen, T., Potter, B. V. L., Ehmke, H. and Guse, A. H., 2012. Forthcoming. Antagonism of NAADP mediated calcium signaling ameliorates arrythmias in the heart. Circulation

Sureshan, K. M., Riley, A. M., Thomas, M. P., Tovey, S. C., Taylor, C. W. and Potter, B. V. L., 2012. Contribution of phosphates and adenine to the potency of adenophostins at the IP 3 receptor:synthesis of all possible bisphosphates of adenophostin A. Journal of Medicinal Chemistry, 55 (4), pp. 1706-1720.

Turner, B. L., Cheesman, A. W., Godage, H. Y., Riley, A. M. and Potter, B. V. L., 2012. Determination of neo-and D-chiro-inositol hexakisphosphate in soils by solution 31P NMR spectroscopy. Environmental Science & Technology, 46 (9), pp. 4994-5002.

Leese, M. P., Jourdan, F., Dohle, W., Kimberley, M. R., Thomas, M. P., Bai, R., Hamel, E., Ferrandis, E. and Potter, B. V. L., 2012. Steroidomimetic tetrahydroisoquinolines for the design of new microtubule disruptors. ACS Medicinal Chemistry Letters, 3 (1), pp. 5-9.

Swarbrick, J. M. and Potter, B. V. L., 2012. Total synthesis of a cyclic adenosine 5′-diphosphate ribose receptor agonist. Journal of Organic Chemistry, 77 (9), pp. 4191-4197.

Woo, L. W. L., Ganeshapillai, D., Thomas, M. P., Sutcliffe, O. B., Malini, B., Mahon, M. F., Purohit, A. and Potter, B. V. L., 2011. Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor irosustat (STX64, BN83495). ChemMedChem, 6 (11), pp. 2019-2034.

Su, X., Pradaux-Caggiano, F., Vicker, N., Thomas, M. P., Halem, H., Culler, M. D. and Potter, B. V. L., 2011. Adamantyl ethanone pyridyl derivatives:potent and selective inhibitors of human 11 beta-hydroxysteroid dehydrogenase type 1. ChemMedChem, 6 (9), pp. 1616-1629.

Wood, P. M., Woo, L. W. L., Thomas, M. P., Mahon, M. F., Purohit, A. and Potter, B. V. L., 2011. Aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole and vorozole templates. ChemMedChem, 6 (8), pp. 1423-1438.

Su, X., Vicker, N., Thomas, M. P., Pradaux-Caggiano, F., Halem, H., Culler, M. D. and Potter, B. V. L., 2011. Discovery of adamantyl heterocyclic ketones as potent 11 beta-hydroxysteroid dehydrogenase type 1 inhibitors. ChemMedChem, 6 (8), pp. 1439-1451.

Jourdan, F., Leese, M. P., Dohle, W., Ferrandis, E., Newman, S. P., Chander, S., Purohit, A. and Potter, B. V. L., 2011. Structure-activity relationships of C-17-substituted estratriene-3-O-sulfamates as anticancer agents. Journal of Medicinal Chemistry, 54 (13), pp. 4863-4879.

Woo, L. W. L., Purohit, A. and Potter, B. V. L., 2011. Development of steroid sulfatase inhibitors. Molecular and Cellular Endocrinology, 340 (2), pp. 175-185.

Purohit, A., Woo, L. W. L. and Potter, B. V. L., 2011. Steroid sulfatase:a pivotal player in estrogen synthesis and metabolism. Molecular and Cellular Endocrinology, 340 (2), pp. 154-160.

Falasca , Marco, 2011. Novel Inositol Phosphate Derivatives. A61K31/661- WO2011064559 (A2), 03 June 2011.

Thomas, M. P. and Potter, B. V. L., 2011. Crystal structures of II beta-hydroxysteroid dehydrogenase type I and their use in drug discovery. Future Medicinal Chemistry, 3 (3), pp. 367-390.

Woo, L. W. L., Bubert, C., Purohit, A. and Potter, B. V. L., 2011. Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity. ACS Medicinal Chemistry Letters, 2 (3), pp. 243-247.

Moreau, C., Ashamu, G. A., Bailey, V. C., Galione, A., Guse, A. H. and Potter, B. V. L., 2011. Synthesis of cyclic adenosine 5 '-diphosphate ribose analogues:a C2 ' endo/syn "southern" ribose conformation underlies activity at the sea urchin cADPR receptor. Organic and Biomolecular Chemistry, 9 (1), pp. 278-290.

Newman, S. P., Day, J. M., Potter, B. V. L., Reed, M. J. and Purohit, A., 2011. Forthcoming. The effects of paclitaxel and STX140 on early-and late-stage breast cancer in tte clinically relevant C3(1)/SV40 mouse model. European Journal of Cancer

Koob, Z., Perez, A., Bascompta, E., Soulard, C., Caroline, C., Hillairet de Boisferon, M., Woo, L. W. L., Potter, B. V. L., Reed, M. J., Ali, T., Bichat, F. and Prevost, G., 2011. Forthcoming. The steroid sulfatase inhibitor BN-83495 inhibits the growth of DMBA induced mammary tumors in rats alone or in combination with estradiol receptor blockers. Breast Cancer Research and Treatment

Leese, M. P., Jourdan, F., Ferrandis, E., Regis-Lydi, S., Kasprzyk, P. G., Stengel, C., Newman, S. P., Purohit, A., Reed, M. J. and Potter, B. V. L., 2010. Optimisation of tetrahydroisoquinoline based microtubule disruptors as anti-cancer agents. EJC Supplements, 8 (7), p. 141.

Rossi, A. M., Sureshan, K. M., Riley, A. M., Potter, B. V. L. and Taylor, C. W., 2010. Selective determinants of inositol 1,4,5-trisphosphate and adenophostin A interactions with type 1 inositol 1,4,5-trisphosphate receptors. British Journal of Pharmacology, 161 (5), pp. 1070-1085.

Wood, P. M., Woo, L. W. L., Labrosse, J.-R., Thomas, M. P., Mahon, M. F., Chander, S. K., Purohit, A., Reed, M. J. and Potter, B. V. L., 2010. Bicyclic derivatives of the potent dual aromatase-steroid sulfatase inhibitor 2-bromo-4-{ (4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino methyl}phenylsul famate:synthesis, SAR, crystal structure, and in vitro and in vivo activities. ChemMedChem, 5 (9), pp. 1577-1593.

Su, X., Pradaux-Caggiano, F., Thomas, M. P., Szeto, M. W. Y., Halem, H. A., Culler, M. D., Vicker, N. and Potter, B. V. L., 2010. Discovery of adamantyl ethanone derivatives as potent 11β-hydroxysteroid dehydrogenase Type 1 (11β-HSD1) inhibitors. ChemMedChem, 5 (7), pp. 1026-1044.

Cordiglieri, C., Odoardi, F., Zhang, B., Nebel, M., Kawakami, N., Klinkert, W. E. F., Lodygin, D., Luhder, F., Breunig, E., Schild, D., Ulaganathan, V. K., Dornmair, K., Dammermann, W., Potter, B. V. L., Guse, A. H. and Flugel, A., 2010. Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. Brain, 133 (7), pp. 1930-1943.

Leese, M. P., Jourdan, F., Kimberley, M. R., Cozier, G. E., Thiyagarajan, N., Stengel, C., Regis-Lydi, S., Foster, P. A., Newman, S. P., Acharya, K. R., Ferrandis, E., Purohit, A., Reed, M. J. and Potter, B. V. L., 2010. Chimeric microtubule disruptors. Chemical Communications, 46 (17), pp. 2907-2909.

Raimondi, C., Maffucci, T., Potter, B. V. L. and Falasca, M., 2010. A novel and selective PDK1 inhibitor reduces breast cancer cell invasion and tumour growth. Breast Cancer Research, 12 (Supplement 1), S3.

Cozier, G. E., Leese, M. P., Lloyd, M. D., Baker, M. D., Thiyagarajan, N., Acharya, K. R. and Potter, B. V. L., 2010. Structures of human carbonic anhydrase II/inhibitor complexes reveal a second binding site for steroidal and nonsteroidal inhibitors. Biochemistry, 49 (16), pp. 3464-3476.

Jourdan, F., Leese, M. P., Dohle, W., Hamel, E., Ferrandis, E., Newman, S. P., Purohit, A., Reed, M. J. and Potter, B. V. L., 2010. Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-Methoxyestradiol-3,17-O,O-bis-sulfamate. Journal of Medicinal Chemistry, 53 (7), pp. 2942-2951.

Woo, L. .W. L., Jackson, T., Putey, A., Cozier, G., Leonard, P., Acharya, K. R., Chander, S. K., Purohit, A., Reed, M. J. and Potter, B. V. L., 2010. Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. Journal of Medicinal Chemistry, 53 (5), pp. 2155-2170.

Falasca, M., Chiozzotto, D., Godage, H. Y., Mazzoletti, M., Riley, A. M., Previdi, S., Potter, B. V. L., Broggini, M. and Maffucci, T., 2010. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. British Journal of Cancer, 102 (1), pp. 104-114.

Stengel, C., Newman, S. P., Leese, M. P., Potter, B. V. L., Reed, M. J. and Purohit, A., 2010. Class III β-tubulin expression and in vitro resistance to microtubule targeting agents. British Journal of Cancer, 102 (2), pp. 316-324.

Rossi, A. M., Riley, A. M., Potter, B. V. L. and Taylor, C. W., 2010. Adenophostins:high-affinity agonists of IP3 receptors. Current Topics in Membranes, 66, pp. 209-233.

Ding, Z., Rossi, A. M., Riley, A. M., Rahman, T., Potter, B. V. L. and Taylor, C. W., 2010. Binding of inositol 1,4,5-trisphosphate (IP3) and adenophostin A to the N-terminal region of the (IP3) receptor:thermodynamic analysis using fluorescence polarization with a novel (IP3) receptor ligand. Molecular Pharmacology, 77 (6), pp. 995-1004.

Foster, P. A., Ho, Y. T., Newman, S. P., Leese, M. P., Potter, B. V. L., Reed, M. J. and Purohit, A., 2009. STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells. Anticancer Research, 29 (10), pp. 3751-3757.

Liu, Q., Graeff, R., Kriksunov, I. A., Jiang, H., Zhang, B., Oppenheimer, N., Lin, H. N., Potter, B. V. L., Lee, H. C. and Hao, Q., 2009. Structural basis for enzymatic evolution from a dedicated ADP-ribosyl cyclase to a multifunctional NAD Hydrolase. Journal of Biological Chemistry, 284 (40), pp. 27637-27645.

Rossi, A. M., Riley, A. M., Tovey, S. C., Rahman, T., Dellis, O., Taylor, E. J. A., Veresov, V. G., Potter, B. V. L. and Taylor, C. W., 2009. Synthetic partial agonists reveal key steps in IP3 receptor activation. Nature Chemical Biology, 5 (9), pp. 631-639.

Dammermann, W., Zhang, B., Nebel, M., Cordiglieric, C., Odoardi, F., Kirchberger, T., Kawakami, N., Dowden, J., Schmid, F., Dornmair, K., Hohenegger, M., Flugel, A., Guse, A. H. and Potter, B. V. L., 2009. NAADP-mediated Ca2+ signaling via type 1 ryanodine receptor in T cells revealed by a synthetic NAADP antagonist. Proceedings of the National Academy of Sciences of the United States of America, 106 (26), pp. 10678-10683.

Vicker, N., Sharland, C. M., Heaton, W. B., Ramos Gonzalez, A. M., Bailey, H. V., Smith, A., Springall, J. S., Day, J. M., Tutill, H. J., Reed, M. J., Purohit, A. and Potter, B. V. L., 2009. The design of novel 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors. Molecular and Cellular Endocrinology, 301 (1-2), pp. 259-265.

Sureshan, K. M., Riley, A. M., Rossi, A. M., Tovey, S. C., Dedos, S. G., Taylor, C. W. and Potter, B. V. L., 2009. Activation of IP3 receptors by synthetic bisphosphate ligands. Chemical Communications, 2009 (10), pp. 1204-1206.

Su, X., Vicker, N., Trusselle, M., Halem, H., Culler, M. D. and Potter, B. V. L., 2009. Discovery of novel inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. Molecular and Cellular Endocrinology, 301 (1-2), pp. 169-173.

Day, J. M., Foster, P. A., Tutill, H. J., Newman, S. P., Ho, Y. T., Leese, M. P., Potter, B. V. L., Reed, M. J. and Purohit, A., 2009. BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure. British Journal of Cancer, 100 (3), pp. 476-486.

Kirchberger, T., Moreau, C., Wagner, G. K., Fliegert, R., Siebrands, C. C., Nebel, M., Schmid, F., Harneit, A., Odoardi, F., Flugel, A., Potter, B. V. L. and Guse, A. H., 2009. 8-Bromo-cyclic inosine diphosphoribose:towards a selective cyclic ADP-ribose agonist. Biochemical Journal, 422 (1), pp. 139-149.

Abbate, S., Longhi, G., Castiglioni, E., Lebon, F., Wood, P. M., Woo, L. W. L. and Potter, B. V. L., 2009. Determination of the absolute configuration of aromatase and dual aromatase-sulfatase inhibitors by vibrational and electronic circular dichroism spectra analysis. Chirality, 21 (9), pp. 802-808.

Day, J. M., Tutill, H. J., Foster, P. A., Bailey, H. V., Heaton, W. B., Sharland, C. M., Vicker, N., Potter, B. V. L., Purohit, A. and Reed, M. J., 2009. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17β-hydroxysteroid dehydrogenase Type 3. Molecular and Cellular Endocrinology, 301 (1-2), pp. 251-258.

Veiga, N., Torres, J., Godage, H. Y., Riley, A. M., Dominguez, S., Potter, B. V. L., Diaz, A. and Kremer, C., 2009. The behaviour of inositol 1,3,4,5,6-pentakisphosphate in the presence of the major biological metal cations. Journal of Biological Inorganic Chemistry, 14 (7), pp. 1001-1013.

Day, J. M., Purohit, A., Tutill, H. J., Foster, P. A., Woo, L. W. L., Potter, B. V. L. and Reed, M. J., 2009. The development of steroid sulfatase iInhibitors for hormone-dependent cancer therapy. In: Bradlow, H. L. and Carruba, G., eds. Steroid Enzymes and Cancer.Vol. 1155. Blackwell Publishing, pp. 80-87.

Foster, P. A., Chander, S. K., Newman, S. P., Woo, L. W. L., Sutcliffe, O. B., Bubert, C., Zhou, D. J., Chen, S. A., Potter, B. V. L., Reed, M. J. and Purohit, A., 2008. A new therapeutic strategy against hormone-dependent breast cancer:the preclinical development of a dual aromatase and sulfatase inhibitor. Clinical Cancer Research, 14 (20), pp. 6469-6477.

Parsons, M. F. C., Foster, P. A., Chander, S. K., Jhalli, R., Newman, S. P., Leese, M. P., Potter, B. V. L., Purohit, A. and Reed, M. J., 2008. The in vivo properties of STX243:A potent angiogenesis inhibitor in breast cancer. British Journal of Cancer, 99 (9), pp. 1433-1441.

Kudoh, T., Murayama, T., Hashii, M., Higashida, H., Sakurai, T., Maechling, C., Spiess, B., Weber, K., Guse, A. H. and Potter, B. V. L., 2008. Design and synthesis of 4″,6″-unsaturated cyclic ADP-carbocyclic-ribose, a Ca2+-mobilizing agent selectively active in T cells. Tetrahedron, 64 (41), pp. 9754-9765.

Bubert, C., Woo, L. W. L., Sutcliffe, O. B., Mahon, M. F., Chander, S. K., Purohit, A., Reed, M. J. and Potter, B. V. L., 2008. Synthesis of aromatase inhibitors and dual aromatase steroid sulfatase inhibitors by linking an arylsulfamate motif to 4-(4H-1,2,4-triazol-4-ylamino)benzonitrile:SAR, crystal structures, in vitro and in vivo activities. ChemMedChem, 3 (11), pp. 1708-1730.

Reed, M. J., Purohit, A., Woo, L. W. L. and Potter, B. V. L., 2008. Steroid sulfatase inhibitors for the tropical treatment of skin disorders. Drugs of the Future, 33 (7), pp. 597-606.

Newman, S. P., Foster, P. A., Stengel, C., Day, J. M., Ho, Y. T., Judde, J.-G., Lassalle, M., Prevost, G., Leese, M. P., Potter, B. V. L., Reed, M. J. and Purohit, A., 2008. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clinical Cancer Research, 14 (2), pp. 597-606.

Fusi, L., Purohit, A., Brosens, J., Woo, L. W. L., Potter, B. V. L. and Reed, M. J., 2008. Inhibition of steroid sulfatase activity in endometriotic Implants by STX64 (667Coumate):a potential new therapy. The Scientific World Journal, 8, pp. 1325-1327.

Day, J. M., Foster, P. A., Tutill, H. J., Parsons, M. F. C., Newman, S. P., Chander, S. K., Allan, G. M., Lawrence, H. R., Vicker, N., Potter, B. V. L., Reed, M. J. and Purohit, A., 2008. 17β-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. International Journal of Cancer, 122 (9), pp. 1931-1940.

Su, X., Vicker, N. and Potter, B. V. L., 2008. 2 inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Progress in Medicinal Chemistry, 46, pp. 29-130.

Zhang, B., Wagner, G. K., Weber, K., Garnham, C., Morgan, A. J., Galione, A., Guse, A. H. and Potter, B. V. L., 2008. 2'-Deoxy clyclic adenosine 5'-diphosphate ribose derivatives:importance of the 2'-hydroxyl motif for the antagonistic activity of 8-substituted cADPR derivatives. Journal of Medicinal Chemistry, 51 (6), pp. 1623-1636.

Foster, P. A., Ho, Y. T., Newman, S. P., Kasprzyk, P. G., Leese, M. P., Potter, B. V. L., Reed, M. J. and Purohit, A., 2008. 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Research and Treatment, 111 (2), pp. 251-260.

Tagg, S. L. C., Foster, P. A., Leese, M. P., Potter, B. V. L., Reed, M. J., Purohit, A. and Newman, S. P., 2008. 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination:a potential treatment for breast and prostate cancer. British Journal of Cancer, 99 (11), pp. 1842-1848.

Sureshan, K. M., Trusselle, M., Tovey, S. C., Taylor, C. W. and Potter, B. V. L., 2008. 2-Position base-modified analogues of adenophostin A as high-affinity agonists of the D-myo-inositol trisphosphate receptor:in vitro evaluation and molecular modeling. Journal of Organic Chemistry, 73 (5), pp. 1682-1692.

Foster, P. A., Stengel, C., Ali, T., Leese, M. P., Potter, B. V. L., Reed, M. J., Purohit, A. and Newman, S. P., 2008. A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anticancer Research, 28 (3A), pp. 1483-1491.

Foster, P. A., Newman, S. P., Leese, M. P., Bernetiere, S., Diolez, C., Camara, J., Hacher, B., Baronnet, M.-M., Ali, T., Potter, B. V. L., Reed, M. J. and Purohit, A., 2008. A new micronized formulation of 2-methoxyestradiol- bis -sulfamate (STX140) is therapeutically potent against breast cancer. Anticancer Research, 28 (2A), pp. 577-581.

Woo, L. W. L., Fischer, D. S., Sharland, C. M., Trusselle, M., Foster, P. A., Chander, S. K., Di Fiore, A., Supuran, C. T., De Simone, G., Purohit, A., Reed, M. J. and Potter, B. V. L., 2008. Anticancer steroid sulfatase inhibitors:synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography. Molecular Cancer Therapeutics, 7 (8), pp. 2435-2444.

Mills, S. J., Vandeput, F., Trusselle, M. N., Safrany, S. T., Erneux, C. and Potter, B. V. L., 2008. Benzene polyphosphates as tools for cell signalling: inhibition of inositol 1,4,5‐trisphosphate 5‐phosphatase and interaction with the PH domain of protein kinase Bα. ChemBiochem, 9 (11), pp. 1757-1766.

Zhang, B., Bailey, V. C. and Potter, B. V. L., 2008. Chemoenzymatic synthesis of 7-deaza cyclic adenosine 5'-diphosphate ribose anlaogues, membrane-permeant modulators of intracellular calcium release. Journal of Organic Chemistry, 73 (5), pp. 1693-1703.

Wood, P. M., Woo, L. W. L., Labrosse, J.-R., Trusselle, M. N., Abbate, S., Longhi, G., Castiglioni, E., Lebon, F., Purohit, A., Reed, M. J. and Potter, B. V. L., 2008. Chiral aromatase and dual aromatase−steroid sulfatase inhibitors from the letrozole template:synthesis, absolute configuration, and in vitro activity. Journal of Medicinal Chemistry, 51 (14), pp. 4226-4238.

Kudoh, T., Weber, K., Guse, A. H., Potter, B. V. L., Hashii, M., Higashida, H., Arisawa, M., Matsuda, A. and Shuto, S., 2008. Design and synthesis of 4",6"-unsaturated cyclic ADP-carbocyclic ribose as a Ca 2+-mobilizing agent. Tetrahedron Letters, 49 (25), pp. 3976-3979.

Bojarová, P., Denehy, E., Walker, I., Loft, K., De Souza, D. P., Woo, L. W. L., Potter, B. V. L., McConville, M. J. and Williams, S. J., 2008. Direct evidence for ArO-S bond cleavage upon inactivation of Pseudomonas aeruginosa Arylsulfatase by Aryl Sulfamates. ChemBiochem, 9 (4), pp. 613-623.

Jourdan, F., Bubert, C., Leese, M. P., Smith, A., Ferrandis, E., Regis-Lydi, S., Newman, S. P., Purohit, A., Reed, M. J. and Potter, B. V. L., 2008. Effects of C-17 heterocyclic substituents on the anticancer activity of 2-ethylestra-1,3,5(10)-triene-3-O-sulfamates:synthesis, in vitro evaluation and computational modelling. Organic and Biomolecular Chemistry, 6 (22), pp. 4108-4119.

Foster, P. A., Chander, S. K., Parsons, M. F. C., Newman, S. P., Woo, L. W. L., Potter, B. V. L., Reed, M. J. and Purohit, A., 2008. Efficacy of three potent steroid sulfatase inhibitors:pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Research and Treatment, 111 (1), pp. 129-138.

Purohit, A., Fusi, L., Brosens, J., Woo, L. W. L., Potter, B. V. L. and Reed, M. J., 2008. Inhibition of steroid sulfatase activity in endometriotic implants by (667Coumate):a potential new therapy. Human Reproduction, 23 (2), pp. 290-297.

Purohit, A., Chander, S. K., Woo, L. W. L., Parsons, M. F. C., Jhalli, R., Potter, B. V. L. and Reed, M. J., 2008. Inhibition of steroid sulphatase activity via the percutaneous route:a new option for breast cancer therapy. Anticancer Research, 28 (3A), pp. 1517-1523.

Jackson, T., Woo, L. W. L., Trusselle, M. N., Purohit, A., Reed, M. J. and Potter, B. V. L., 2008. Non-steroidal aromatase inhibitors based on a biphenyl scaffold:synthesis, in vitro SAR, and molecular modelling. ChemMedChem, 3 (4), pp. 603-618.

Jackson, T., Woo, L. W. L., Trusselle, M. N., Purohit, A., Reed, M. J. and Potter, B. V. L., 2008. Non-steroidal aromatase inhibitors based ona biphenyl scaffold: synthesis, in vitro SAR, and molecular modelling. ChemMedChem, 3, pp. 603-618.

Allan, G. M., Vicker, N., Lawrence, H. R., Tutill, H. J., Day, J. M., Huchet, M., Ferrandis, E., Reed, M. J., Purohit, A. and Potter, B. V. L., 2008. Novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1:templates for design. Bioorganic and Medicinal Chemistry, 16 (8), pp. 4438-4456.

Leese, M. P., Jourdan, F. L., Gaukroger, K., Mahon, M. F., Newman, S. P., Foster, P. A., Stengel, C., Regis-Lydi, S., Ferrandis, E., Di Fiore, A., De Simone, G., Supuran, C. T., Purohit, A., Reed, M. J. and Potter, B. V. L., 2008. Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. Journal of Medicinal Chemistry, 51 (5), pp. 1295-1308.

Foster, P. A., Woo, L. W. L., Potter, B. V. L., Reed, M. J. and Purohit, A., 2008. The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology, 149 (8), pp. 4035-4042.

This list was generated on Mon Oct 23 11:03:19 2017 IST.

View more publications »